RTW Biotech portfolio co Aktis Oncology raises $318m in IPO

(Sharecast News) - Life sciences investor RTW Biotech Opportunities said its private portfolio company Aktis Oncology had raised $318m via an IPO. Aktis offered 17.65 million shares at $18 each, representing a 2.6% step-up from RTW Bio's prior holding value at November 30 and a18.3% step-up from the cost at the time of purchase in September 2024.

Aktis started trading on the Nasdaq global select market on January 9, where the stock traded up 24.4% to close at $22.40 per share.

The clinical-stage oncology company is focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations. Its lead programme targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumour types, RTW said on Monday.

Reporting by Frank Prenesti for Sharecast.com